JP7187317B2 - 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物 - Google Patents

腎疾患及び歯周疾患を検出及び診断するための方法及び組成物 Download PDF

Info

Publication number
JP7187317B2
JP7187317B2 JP2018545645A JP2018545645A JP7187317B2 JP 7187317 B2 JP7187317 B2 JP 7187317B2 JP 2018545645 A JP2018545645 A JP 2018545645A JP 2018545645 A JP2018545645 A JP 2018545645A JP 7187317 B2 JP7187317 B2 JP 7187317B2
Authority
JP
Japan
Prior art keywords
polypeptide
cystatin
sample
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508694A (ja
JP2019508694A5 (enExample
Inventor
イエラミッリ，マハーラクシュミー
ファラス，ジョシ
クイン，ジョン，ジョセフ
イエラミッリ，マーティ，ヴィー．エス．エヌ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Publication of JP2019508694A publication Critical patent/JP2019508694A/ja
Publication of JP2019508694A5 publication Critical patent/JP2019508694A5/ja
Priority to JP2021184696A priority Critical patent/JP7598843B2/ja
Application granted granted Critical
Publication of JP7187317B2 publication Critical patent/JP7187317B2/ja
Priority to JP2023203767A priority patent/JP2024028816A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/348—Urinary tract infections
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
JP2018545645A 2016-03-02 2017-03-02 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物 Active JP7187317B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021184696A JP7598843B2 (ja) 2016-03-02 2021-11-12 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
JP2023203767A JP2024028816A (ja) 2016-03-02 2023-12-01 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302299P 2016-03-02 2016-03-02
US62/302,299 2016-03-02
PCT/US2017/020377 WO2017151871A1 (en) 2016-03-02 2017-03-02 Methods and compositions for the detection and diagnosis of renal disease and periodontal disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021184696A Division JP7598843B2 (ja) 2016-03-02 2021-11-12 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2019508694A JP2019508694A (ja) 2019-03-28
JP2019508694A5 JP2019508694A5 (enExample) 2020-04-09
JP7187317B2 true JP7187317B2 (ja) 2022-12-12

Family

ID=58410448

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018545645A Active JP7187317B2 (ja) 2016-03-02 2017-03-02 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
JP2021184696A Active JP7598843B2 (ja) 2016-03-02 2021-11-12 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
JP2023203767A Pending JP2024028816A (ja) 2016-03-02 2023-12-01 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021184696A Active JP7598843B2 (ja) 2016-03-02 2021-11-12 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
JP2023203767A Pending JP2024028816A (ja) 2016-03-02 2023-12-01 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物

Country Status (16)

Country Link
US (3) US10725052B2 (enExample)
EP (2) EP4299586A3 (enExample)
JP (3) JP7187317B2 (enExample)
KR (2) KR102311590B1 (enExample)
CN (1) CN108700600B (enExample)
AR (2) AR107786A1 (enExample)
AU (1) AU2017225758B2 (enExample)
BR (1) BR112018067292A2 (enExample)
CA (1) CA3016163A1 (enExample)
DK (1) DK3423838T5 (enExample)
ES (1) ES2970868T3 (enExample)
MX (2) MX2018010536A (enExample)
NZ (1) NZ745263A (enExample)
TW (1) TWI822655B (enExample)
WO (1) WO2017151871A1 (enExample)
ZA (1) ZA201806418B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024028816A (ja) * 2016-03-02 2024-03-05 アイデックス ラボラトリーズ インコーポレイテッド 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
JP7207585B2 (ja) * 2017-09-01 2023-01-18 株式会社三洋物産 遊技機
CN110938130B (zh) * 2019-11-08 2021-07-09 上海交通大学 一种生物活性多肽rvfqplphenkpltl及其制备方法和应用
EP4136141A4 (en) 2020-04-17 2024-09-11 IDEXX Laboratories, Inc. Fluorescence quenching immunossay
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機
EP4469799A2 (en) * 2022-01-26 2024-12-04 IDEXX Laboratories, Inc. Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease
TWI882593B (zh) * 2022-12-23 2025-05-01 高雄醫學大學 上泌尿道結石風險評估模型建立方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527478A (ja) 2010-06-03 2013-06-27 アイデックス ラボラトリーズ インコーポレイテッド 腎疾患のためのマーカー

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
NL1020962C2 (nl) 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US20070087448A1 (en) 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
AU2006207954A1 (en) * 2005-01-28 2006-08-03 Childrens Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
CA2596469A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2007013575A2 (en) 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
CN101120904B (zh) 2006-11-13 2011-06-29 李复生 癌症疾病治疗器
EP2535718B1 (en) 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
CA2739076A1 (en) * 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
WO2010057184A2 (en) * 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Methods for detection of acute kidney injury in humans
CN102713632B (zh) 2009-12-23 2015-10-07 希尔氏宠物营养品公司 用于诊断和治疗犬肾脏病症的组合物和方法
KR101222437B1 (ko) * 2010-03-17 2013-01-15 경북대학교 산학협력단 바이오마커
CN101937000A (zh) * 2010-08-05 2011-01-05 北京倍爱康生物技术有限公司 一种人胱抑素c的磁微粒分离化学发光免疫分析检测方法
AU2017225758B2 (en) * 2016-03-02 2023-03-16 Idexx Laboratories, Inc. Methods and compositions for the detection and diagnosis of renal disease and periodontal disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527478A (ja) 2010-06-03 2013-06-27 アイデックス ラボラトリーズ インコーポレイテッド 腎疾患のためのマーカー

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024028816A (ja) * 2016-03-02 2024-03-05 アイデックス ラボラトリーズ インコーポレイテッド 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物

Also Published As

Publication number Publication date
ES2970868T3 (es) 2024-05-31
DK3423838T5 (da) 2024-09-16
KR102311590B1 (ko) 2021-10-12
US10725052B2 (en) 2020-07-28
TWI822655B (zh) 2023-11-21
EP3423838A1 (en) 2019-01-09
MX2023012628A (es) 2023-11-08
ZA201806418B (en) 2019-07-31
CN108700600A (zh) 2018-10-23
KR20210127763A (ko) 2021-10-22
US20250341529A1 (en) 2025-11-06
TW201736850A (zh) 2017-10-16
US12385927B2 (en) 2025-08-12
KR20180114936A (ko) 2018-10-19
JP2019508694A (ja) 2019-03-28
NZ745263A (en) 2022-07-01
CA3016163A1 (en) 2017-09-08
AR131922A2 (es) 2025-05-14
CN108700600B (zh) 2022-06-03
WO2017151871A1 (en) 2017-09-08
JP7598843B2 (ja) 2024-12-12
AR107786A1 (es) 2018-06-06
AU2017225758B2 (en) 2023-03-16
JP2024028816A (ja) 2024-03-05
US20170269101A1 (en) 2017-09-21
EP3423838B1 (en) 2023-11-08
EP4299586A3 (en) 2024-04-03
US20200400683A1 (en) 2020-12-24
JP2022028790A (ja) 2022-02-16
AU2017225758A1 (en) 2018-08-30
EP4299586A2 (en) 2024-01-03
BR112018067292A2 (pt) 2019-01-02
DK3423838T3 (da) 2024-02-05
KR102424496B1 (ko) 2022-07-25
MX2018010536A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
JP7598843B2 (ja) 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
JP6861771B2 (ja) 腎疾患のためのマーカー
JP2021167805A (ja) ＳＡＲＳ−ＣｏＶ−２感染症を診断するための方法および試薬
KR20110000548A (ko) 신장암의 진단 또는 검출을 위한 조성물 및 방법
CN119604763A (zh) 用于区分进展性慢性肾脏疾病与稳定性慢性肾脏疾病的方法和组合物
US10060925B2 (en) Miox antibody and assay
EP2859349B1 (fr) Procédé de détection et/ou de dosage de l'annexine a3 d'un mammifère dans le sang ou un de ses dérivés

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211112

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211124

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211130

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211228

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220111

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220201

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220607

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221004

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221101

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221130

R150 Certificate of patent or registration of utility model

Ref document number: 7187317

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250